Compare VTEX & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTEX | DRUG |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.3M | 778.4M |
| IPO Year | 2019 | 2020 |
| Metric | VTEX | DRUG |
|---|---|---|
| Price | $3.61 | $68.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $5.97 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 738.5K | 116.8K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.78 | N/A |
| Revenue Next Year | $9.63 | N/A |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.84 | $39.70 |
| 52 Week High | $4.73 | $123.75 |
| Indicator | VTEX | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 35.52 |
| Support Level | $3.64 | $64.82 |
| Resistance Level | $3.79 | $77.16 |
| Average True Range (ATR) | 0.13 | 3.63 |
| MACD | 0.00 | -1.39 |
| Stochastic Oscillator | 64.06 | 0.21 |
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.